<DOC>
	<DOCNO>NCT02144701</DOCNO>
	<brief_summary>This randomize pilot clinical trial study Lactobacillus rhamnosus GG reduce incidence graft-versus-host disease patient undergone donor stem cell transplant . Lactobacillus rhamnosus GG may effective prevent graft-versus-host disease cause donor stem cell transplant .</brief_summary>
	<brief_title>Lactobacillus Rhamnosus GG Reducing Incidence Graft-Versus-Host Disease Patients Who Have Undergone Donor Stem Cell Transplant</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine hematopoietic stem cell transplant ( HSCT ) patient treat probiotic ( Lactobacillus GG [ Lactobacillus rhamnosus GG ] ) -containing diet compare assigned receive probiotic low incidence grade 1 upper gastrointestinal ( GI ) grade 2-4 low GI acute graft-versus-host disease ( GVHD ) ( aGVHD ) use Center International Blood Marrow Transplant Research ( CIBMTR ) score prescribe probiotic . II . To determine HSCT patient treat probiotic-containing diet compare assigned receive probiotic : ) low rate organ-specific acute aGVHD ( intestinal tract , skin , liver ) ; b ) low rate moderate severe chronic GVHD ( National Institutes Health [ NIH ] consensus score ) 6 month 1 year post transplant ; c ) short duration immunosuppressive therapy ( normalized age degree human leukocyte antigen [ HLA ] match ) ; ) low rate bacterial and/or opportunistic infection . SECONDARY OBJECTIVES : I . To determine allogeneic hematopoietic stem cell patient treat probiotic compare assigned receive probiotic difference : ) composition proportion major gut bacterial phylotypes stool ( analyzed change pre- post-initiation probiotic association development aGVHD ) ; b ) measure inflammation assess cytokine receptor production ( interleukin [ IL ] -6 , IL-8 , tumor necrosis factor [ TNF ] -alpha , TNF-receptor 1 , interferon-gamma , IL-2R , IL-10 ) ; c ) qualitative measure immune reconstitution determine sequential measurement conventional T cell , regulatory T regulatory , B cell natural killer ( NK ) cell ; ) antibody class/subclass production ; e ) biomarkers associate GVHD-elafin , regenerate islet-derived 3 alpha ( Reg3a ) , suppressor tumorigenicity-2 ( ST2 ) , hepatocyte growth factor ( HGF ) ; and/or urinary tryptophan metabolite ; f ) marker gut barrier function include blood level endotoxin microbial deoxyribonucleic acid ( DNA ) . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients receive Lactobacillus rhamnosus GG orally ( PO ) daily ( QD ) 1 year . ARM II : Patients receive intervention .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<criteria>Able sign inform consent Undergoing allogeneic HSCT relate unrelated donor Hematopoietic engraftment evidence recovery absolute neutrophil count great 500/mm^3 &gt; 3 day without filgrastim ( GCSF ) support within 40 day transplant ( i.e . complete blood count [ CBCs ] obtain 3 day apart GCSF must demonstrate absolute neutrophil count &gt; 500/mm^3 ) ; absolute neutropenia achieve due nonmyeloablative transplant , patient enrol day +21 +40 Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Evidence GVHD time enrollment assess clinically Serum creatinine great 3.0 Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) great 3 time upper limit normal Total bilirubin great 2 time upper limit normal Prior use probiotic within 3 month prior enrollment Inability take medication mouth Prior history inflammatory bowel disease chronic diarrheal illness Prior history hypersensitivity milk protein Active Clostridium difficile infection prophylactic tapering antibiotic Clostridium difficile infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>